When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan-Reference-Cited by-同舟云学术

When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan

Published:2024-08-25 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Schulte Brian C.¹²^ORCID,Hwang Caleb³^ORCID,Horvai Andrew E.¹⁴,Olivier Timothee⁵

Affiliation:

1. Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California USA

2. Division of Hematology and Oncology Department of Medicine University of California San Francisco San Francisco California USA

3. School of Medicine University of California San Francisco San Francisco California USA

4. Department of Pathology and Laboratory Medicine University of California San Francisco San Francisco California USA

5. Department of Oncology Geneva University Hospital Geneva Switzerland

Abstract

In April 2024, the Food and Drug Administration provided accelerated approval for Trastuzumab Deruxtecan for adult patients with advanced solid tumors which have positive immunochemical staining (IHC3+) for HER2 expression, including sarcomas. There should be ample consideration prior to utilization of trastuzumab deruxtecan for patients with sarcomas, as HER2 targeted therapy has been ineffective in certain subtypes.

Publisher

Wiley

Reference34 articles.

1. US Food and Drug Administration (FDA).FDA grants accelerated approval to fam‐trastuzumab deruxtecan‐nxki for unresectable or metastatic HER2‐positive solid tumors. FDA;2024. Accessed May 5 2024.https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐grants‐accelerated‐approval‐fam‐trastuzumab‐deruxtecan‐nxki‐unresectable‐or‐metastatic‐her2

2. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial